Diplomat Pharmacy, Inc. (DPLO) EPS Estimated At $0.22

November 1, 2018 – By Michael Collier

Investors sentiment increased to 1.16 in Q2 2018. Its up 0.16, from 1 in 2018Q1. It improved, as 26 investors sold Diplomat Pharmacy, Inc. shares while 56 reduced holdings. 33 funds opened positions while 62 raised stakes. 58.46 million shares or 6.80% more from 54.74 million shares in 2018Q1 were reported.
First Interstate Fincl Bank holds 1,008 shares. Deutsche Bankshares Ag holds 0.01% or 397,143 shares. Guggenheim Capital Limited Liability Corp invested in 11,530 shares. Gotham Asset Mngmt Limited has invested 0% in Diplomat Pharmacy, Inc. (NYSE:DPLO). Daruma Capital Limited Liability Company holds 0.98% of its portfolio in Diplomat Pharmacy, Inc. (NYSE:DPLO) for 592,659 shares. Hood River Cap Mgmt Ltd Liability Co holds 0.81% or 615,905 shares. Us Bancorp De owns 3,399 shares. Pier Limited accumulated 1.27% or 362,328 shares. Tower Rech (Trc) owns 5,700 shares or 0.01% of their US portfolio. Walleye Trading Limited invested in 0% or 27,656 shares. Assetmark holds 1,466 shares or 0% of its portfolio. Federated Pa invested in 0% or 1,917 shares. Rice Hall James Assocs Limited Com has invested 0.76% of its portfolio in Diplomat Pharmacy, Inc. (NYSE:DPLO). Vanguard Group stated it has 5.25 million shares. Ftb holds 755 shares or 0% of its portfolio.

Since May 23, 2018, it had 0 buys, and 8 insider sales for $6.22 million activity. 13,875 shares were sold by Park Jeffrey G, worth $335,806 on Wednesday, May 23. Another trade for 1,680 shares valued at $40,766 was sold by Tomasello Shawn. Wolin Benjamin had sold 1,679 shares worth $40,744 on Friday, June 1. 1,680 Diplomat Pharmacy, Inc. (NYSE:DPLO) shares with value of $40,767 were sold by KLEPPER KENNETH O. Benjamin Regina M. sold $40,765 worth of stock.

Analysts expect Diplomat Pharmacy, Inc. (NYSE:DPLO) to report $0.22 EPS on November, 6 after the close.They anticipate $0.03 EPS change or 12.00 % from last quarter’s $0.25 EPS. DPLO’s profit would be $16.33M giving it 22.55 P/E if the $0.22 EPS is correct. After having $0.17 EPS previously, Diplomat Pharmacy, Inc.’s badysts see 29.41 % EPS growth. The stock increased 0.30% or $0.06 during the last trading session, reaching $19.84. About 509,512 shares traded. Diplomat Pharmacy, Inc. (NYSE:DPLO) has risen 4.25% since November 1, 2017 and is uptrending. It has underperformed by 11.37% the S&P500.

Diplomat Pharmacy, Inc. (NYSE:DPLO) Ratings Coverage

Among 4 badysts covering Diplomat Pharmacy (NYSE:DPLO), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Diplomat Pharmacy had 4 badyst reports since May 10, 2018 according to SRatingsIntel. The company was maintained on Tuesday, July 3 by Morgan Stanley. As per Friday, June 22, the company rating was maintained by Leerink Swann. The company was upgraded on Thursday, May 10 by J.P. Morgan. The rating was upgraded by JP Morgan to “Overweight” on Thursday, May 10.

Diplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States. The company has market cap of $1.47 billion. The firm stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It has a 450.91 P/E ratio. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial badistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.

By Michael Collier